Mainstream Germline Genetic Testing with Expanded Eligibility for Early Breast Cancer Patients in a Large Integrated Health System.

Autor: Shim V; Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA. veronica.shim@kp.org., Karlea A; Department of Genetics, Oakland, Kaiser Permanente, Oakland, USA., Brenman LM; Department of Genetics, Oakland, Kaiser Permanente, Oakland, USA., Gul J; Division of Research, Oakland, Kaiser Permanente, Oakland, USA., Hoodfar E; Department of Genetics, Sacramento, Kaiser Permanente, Sacramento, USA., Chan TD; Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA., Engeman PC; Department of Surgery, South Sacramento, Kaiser Permanente, Sacramento, USA., Sheldon VM; Department of Surgery, Central Valley, Kaiser Permanente, Modesto, USA., Thorne-Hadfield DM; Department of Radiology, San Rafael, Kaiser Permanente, San Rafael, USA., Odele P; Department of Surgery, San Rafael, Kaiser Permanente, San Rafael, USA., Vuong B; Department of Surgery, South Sacramento, Kaiser Permanente, Sacramento, USA., McEvoy J; Department of Surgery, Central Valley, Kaiser Permanente, Modesto, USA., Chang CK; Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, CA, USA., Kotak D; Department of Medical Oncology, San Rafael, Kaiser Permanente, San Rafael, USA., Habel LA; Division of Research, Oakland, Kaiser Permanente, Oakland, USA.
Jazyk: angličtina
Zdroj: Annals of surgical oncology [Ann Surg Oncol] 2024 Sep 18. Date of Electronic Publication: 2024 Sep 18.
DOI: 10.1245/s10434-024-16223-7
Abstrakt: Background: This study evaluated a new mainstream genetic testing pathway for hereditary cancer, with expanded eligibility for early-stage breast cancer patients.
Methods: The study compared multigene panel (62 genes) germline testing uptake and results for breast cancer patients at 4 pilot sites (n = 502 patients) and 10 non-pilot sites (n = 1792 patients) within Kaiser Permanente Northern California from December 2020, to June 2021. At the pilot sites, breast care coordinators (BCCs) offered and consented patients for testing, with eligibility expanded to include all patients age 65 years or younger. At the non-pilot sites, eligible patients were referred to genetics for pre-test counseling, ordering, and follow-up evaluation with the standard guideline that included all patients age 45 years or younger.
Results: Demographic and disease characteristics were similar at the pilot and non-pilot sites. At the pilot verses non-pilot sites, a higher percentage of patients was tested overall (61.6% vs 31.7%) and across all age groups. The median time from breast biopsy to test result also was reduced (22 vs 33 days, respectively). A higher percentage of patients at the pilot sites was identified as having a pathogenic/likely pathogenic variant (PV/LPV) in a breast cancer-related gene (3.6% vs 1.6%). Although the percentage of total patients tested was nearly twofold higher at the pilot sites than at the non-pilot sites, the percentage of total patients seen by genetics was estimated to be similar (33.7% vs 31.7%).
Conclusion: Mainstream genetic testing of breast cancer patients facilitated by BCCs makes it feasible for a large health care system to expand germline genetic testing to early breast cancer patients age 65 years or younger.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: